Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.37 |
| ▸ | PARP1 | P09874 | 12/20 | 0.36 |
| ▸ | PARP2 | Q9UGN5 | 2/20 | 0.32 |
| ▸ | PIM1 | P11309 | 4/20 | 0.31 |
| ▸ | CDC7 | O00311 | 3/20 | 0.31 |
| ▸ | CSNK2B | P67870 | 3/20 | 0.31 |
| ▸ | CSNK2A1 | P68400 | 3/20 | 0.31 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.31 |
| ▸ | CIT | O14578 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.31 |
| ▸ | GSK3B | P49841 | 1/20 | 0.31 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.31 |
| ▸ | TAOK3 | Q9H2K8 | 1/20 | 0.31 |
| ▸ | GRM5 | P41594 | 4/20 | 0.31 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.30 |
| ▸ | CSF1R | P07333 | 1/20 | 0.30 |
| ▸ | CLK2 | P49760 | 1/20 | 0.30 |
| ▸ | MAP4K2 | Q12851 | 1/20 | 0.30 |
| ▸ | MINK1 | Q8N4C8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19488283 | 0.86 | SCN10A (0.30) | SCN10A | |
| SCHEMBL10201775 | 0.86 | SCN10A (0.52) | SCN10APARP1CDC7DYRK1A | |
| SCHEMBL12406080 | 0.84 | SCN10A (0.39) | SCN10APARP1PARP2PIM1CDC7 | |
| SCHEMBL12406137 | 0.83 | — | — | |
| SCHEMBL19488809 | 0.81 | — | — | |
| SCHEMBL14758535 | 0.79 | SCN10A (0.39) | SCN10APARP1PIM1CDC7CSNK2B | |
| SCHEMBL19488795 | 0.79 | SCN10A (0.45) | SCN10APARP1 | |
| SCHEMBL883164 | 0.77 | SCN10A (0.33) | SCN10A | |
| SCHEMBL19488491 | 0.76 | — | — | |
| SCHEMBL10201770 | 0.75 | SCN10A (0.41) | SCN10APARP1PIM1CDC7CSNK2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2601188-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-10-18 | — | — | EP | disclosed |
| US-8809548-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-08-19 | — | — | US | disclosed |
| US-8809548-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-08-19 | — | — | US | disclosed |
| US-20140205564-A1 | Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2014-07-24 | — | — | US | disclosed |
| US-20140205564-A1 | Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2014-07-24 | — | — | US | disclosed |
| WO-2012018325-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-02-09 | — | — | WO | disclosed |
| US-20100215616-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2010-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100215616-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | SCN10A 4625/4885PARP1 3489/4885PARP2 3720/4885 |
| US-20140205564-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | SCN10A 4625/4885PARP1 3489/4885PARP2 3720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.